Tirzepatide ���子背景与靶点 — Explained

By Editorial Desk · published 2025-09-04 · last reviewed 2025-09-23 · Faq

If you have been reading about albumin binding and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2025-09-23. Where a claim depends on a specific study, the study is described rather than over-claimed.

Tirzepatide 分子背景与靶点

在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。

脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。

该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。

Dual Incretin Receptor Pharmacology

Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.

At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.

Tirzepatide at a glance

Molecular Background and Dual Receptor Action

Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.

Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.

Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.

Related pages on this site

• Sustainable checklist
• Measured index
• Structured toolkit
• Regional notes
• Optimized summary
• Structured report
• Durable handbook
• Material primer

Tirzepatide Pharmacology and Development History

Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.

Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.

The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.

Molecular Background and Receptor Pharmacology

The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.

After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.

Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.

Analytical Methods And Storage Stability

Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.

Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.

The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.

Background from the literature

On 5 January 2026, the Venezuelan government issued an emergency order to police to arrest anyone who supported the US attack and mobilized colectivos (pro-government paramilitaries) who established roadblocks and searched cars and people. Fourteen journalists were detained, but 13 of them were later released. On 6 January, gunfire broke out in Caracas as the ministry of communication announced that police fired upon one of their own military drones "flying without permission" but that the drone suffered no damage.

CH2=CH(NH2)CO2H + H2O → CH3−C(O)CO2H + NH3 N-Acylated derivatives of dehydroalanine, such as are found peptides and related compounds, are stable. One such example is methyl 2-acetamidoacrylate. As a residue in a peptide, dehydroalanine is generated by a post translational modification. The required precursors are serine or cysteine residues, which undergo enzyme-mediated loss of water and hydrogen sulfide, respectively. Most amino acid residues are unreactive toward nucleophiles, but those containing dehydroalanine or some other dehydroamino acids are exceptions. These residues are electrophilic due to the α,β-unsaturated carbonyl, and can, for example, alkylate other amino acids. This activity has made DHA useful synthetically to prepare lanthionine.

Guidelines released by the Clinical Pharmacogenomics Implementation Consortium (CPIC) advise against administering codeine to ultrarapid metabolizers, where this genetic information is available. The CPIC also suggests that codeine use be avoided in poor metabolizers, due to its lack of efficacy in this group. Codeine and its salts are readily absorbed from the gastrointestinal tract, and ingestion of codeine phosphate produces peak plasma concentrations in about one hour. Plasma half life is between 3 and 4 hours, and oral/intramuscular analgesic potency ratio is approximately equal to 1:1.5. The most common conversion ratio, given on equianalgesia charts used in the United States, Canada, the UK, Republic of Ireland, the European Union, Russia and elsewhere as 130 mg IM equals 200 mg PO—both of which are equivalent to 10 mg of morphine sulphate IV and 60 mg of morphine sulphate PO. The salt:freebase ratio of the salts of both drugs in use are roughly equivalent, and do not generally make a clinical difference. Codeine is metabolised by O- and N-demethylation in the liver to morphine and norcodeine. Hydrocodone is also a metabolite of codeine in humans. Codeine and its metabolites are mostly removed from the body by the kidneys, primarily as conjugates with glucuronic acid. The active metabolites of codeine, notably morphine, exert their effects by binding to and activating the μ-opioid receptor. People that can metabolize codeine to an extensive degree could result in a 30 mg dose yielding 4 mg of morphine.

Sources: en.wikipedia.org

Further detail

=== Military === As of 2020, three modified Ilyushin Il-86VKP remained in service with the Russian Air Force, down from four aircraft in 2010. The type had already been operated by and taken over from the former Soviet Air Force.

O-GlcNAc transferase OGTase O-linked N-acetylglucosaminyltransferase Uridine diphospho-N-acetylglucosamine:polypeptide β-N-acetylglucosaminyltransferase Systematic name: UDP-N-α-acetyl-d-glucosamine:[protein]-3-O-N-acetyl-β-d-glucosaminyl transferase

=== Films === The Devil We Know (2018): a documentary detailing the health dangers of PFAS. Dark Waters (2019): a thriller movie based on the corporate defense of PFAS and DuPont. Contaminated: The Carpet Industry's Toxic Legacy (2026): documentary about the history of PFAS and the carpet industry. Everywhere & Forever: Blood. Water. And the Politics of PFAS (2025): a documentary about PFAS and the struggles to manage the contamination. Revealed: How to Poison A Planet (2024): a documentary detailing the negative externalities from PFAS creation.

=== Subcellular localization === The c1orf27 protein is likely cytoplasmic. This was found with 55.5 reliability. The K-NN prediction was k = 9/23 and the protein was found to be 55.6% cytoplasmic, 11.1% mitochondrial, 11.1% vacuolar, 11.1% cytoskeletal, and 11.1% golgi.

Sources: en.wikipedia.org

Supporting material

Dominant genes associated with PD but now believed unlikely to be pathogenic include HTRA2, UCHL1 (PARK5), GIGYF2 (PARK11), and EIF4G1. Autosomal recessive genes include PRKN (PARK2, PARKIN), PINK1 (PARK6), PARK7 (DJ-1), ATP13A2 (PARK9), PLA2G6 (PARK14, IPLA2), FBXO7 (PARK15, FBX7), DNAJC6 (PARK19, DJC6), SYNJ1 (PARK20), and VPS13C (PARK23). Most common risk genes (like GBA) affect both sexes equally. The overall genetic risk for PD appears to be similar for males and females. However, there are sex- and gender-related differences between men and women in PD clinical features, disease development and response to treatment. Men are consistently found to have a higher occurrence of Parkinson's disease, with an estimated prevalence rate 1.5 times greater among males than females across all ages. These differences appear to reflect complex interactions among hormones, gene regulation, and other biological, environmental and sociocultural factors. Some sex-linked factors may differently affect brain activity and dopamine pathways. In adult males, the SRY gene (Sex-determining Region on the Y chromosome) is involved in regulation of dopamine, and SRY overactivity may increase PD risk. In women, hormones such as estrogen have been suggested to have a protective effect against PD, but little research has been done.

Drug development is the process of bringing a new drug to the market once a lead compound has been identified through the process of drug discovery. It includes pre-clinical research (microorganisms/animals) and clinical trials (on humans) and may include the step of obtaining regulatory approval to market the drug. Drug Development Process Discovery: The Drug Development process starts with Discovery, a process of identifying a new medicine. Development: Chemicals extracted from natural products are used to make pills, capsules, or syrups for oral use. Injections for direct infusion into the blood drops for eyes or ears. Preclinical research: Drugs go under laboratory or animal testing, to ensure that they can be used on Humans. Clinical testing: The drug is used on people to confirm that it is safe to use. FDA Review: drug is sent to FDA before launching the drug into the market. FDA post-Market Review: The drug is reviewed and monitored by FDA for the safety once it is available to the public.

==== MODAL ==== The MODAL strategy defines overlap sequences known as "linkers" to reduce the amount of customisation that needs to be done with each DNA fragment. The linkers were designed using the R2oDNA Designer software and the overlap regions were designed to be 45 bp long to be compatible with Gibson assembly and other overlap assembly methods. To attach these linkers to the parts to be assembled, PCR is carried using part-specific primers containing 15 bp prefix and suffix adaptor sequences. The linkers are then attached to the adaptor sequences via a second PCR reaction. To position the DNA fragments, the same linker will be attached to the suffix of the desired upstream fragment and the prefix of the desired downstream fragments. Once the linkers are attached, Gibson assembly, CPEC, or the other overlap assembly methods can all be used to assemble the DNA fragments in the desired order.

Sources: en.wikipedia.org

Frequently asked questions